The exchange of medical knowledge is a founding principle of Mayo Clinic. William J. Mayo, M.D., said it best: “It is a great thing to make scientific discoveries of rare value, but it is even greater to be willing to share these...
The exchange of medical knowledge is a founding principle of Mayo Clinic. William J. Mayo, M.D., said it best: “It is a great thing to make scientific discoveries of rare value, but it is even greater to be willing to share these...
April 2023 - Cellular Therapy and Transfusion Medicine - Insights
This "Pathways" program provides a Clinical Pathology case that includes a history, potential answers, rationale, and relevant references. This case’s sub-specialties are Cellular Therapy and Transfusion Medicine.
Improving diagnosis of rare congenital disorders - Insights
Experts at Mayo Clinic have developed a unique method of testing that combines new technology with novel bioinformatics to promptly detect a group of uncommon genetic conditions that are often difficult to identify.
Inflammatory Bowel Disease - Mayo Clinic Laboratories
Inflammatory bowel disease (IBD) is typically classified as either Crohn's disease or ulcerative colitis based on clinical features, colonoscopy findings, histologic changes, and the anatomical distribution of disease. In some cases,...
Biologic Therapy Testing - Mayo Clinic Laboratories
To monitor for immunogenicity, our reflexive approach first measures the biologic concentration within a patient’s specimen. Then, if necessary, an additional test is performed to assess the presence of antibodies to a specific drug that...
Membranous nephropathy assay: PMND1 - Insights
John Lieske, M.D., describes Mayo Clinic Laboratories' new test for primary membranous nephropathy. PMND1 is a diagnostic cascade that provides a cost-effective approach to detecting antigens known to cause membranous nephropathy — a...
FDA-approved test expands options for Alzheimer's disease - Insights
Joshua Bornhorst, Ph.D., describes the new, FDA-approved Alzheimer's disease (AD) test and how it differs from Mayo Clinic Laboratories' existing AD evaluation. The laboratory will offer both tests, to ensure flexibility and options for...
Communiqué Archives - Page 3 of 4 - Insights
Skip to Content MayoACCESS MayoLINK...
IDH assay facilitates timelier leukemia treatment: Rong He, M.D. - Insights
In this test-specific episode of the "Answers From the Lab" podcast, Rong He, M.D., explains how Mayo Clinic Laboratories' IDHQ test improves upon next generation sequencing for assessing AML treatment options.